{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:41:42Z","timestamp":1789962102017,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific and Technological Research Program of Tianjin Municipal Education Commission","award":["2019ZD025"],"award-info":[{"award-number":["2019ZD025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04571-7","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:56:42Z","timestamp":1771333002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate cancer associated 3 (PCA3) is a potential indicator of the pathological grades of prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Yangyang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4571_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4571_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.semnuclmed.2016.07.002","volume":"46","author":"M Nguyen-Nielsen","year":"2016","unstructured":"Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 2016;46:484\u201390. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.002.","journal-title":"Semin Nucl Med"},{"key":"4571_CR3","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317:2532. https:\/\/doi.org\/10.1001\/jama.2017.7248","journal-title":"JAMA"},{"key":"4571_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.juro.2013.02.021","volume":"190","author":"N Bittner","year":"2013","unstructured":"Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. J Urol. 2013;190:509\u201314. https:\/\/doi.org\/10.1016\/j.juro.2013.02.021.","journal-title":"J Urol"},{"key":"4571_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2006.03.026","volume":"50","author":"J Walz","year":"2006","unstructured":"Walz J, Graefen M, Chun FK-H, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol. 2006;50:498\u2013505. https:\/\/doi.org\/10.1016\/j.eururo.2006.03.026.","journal-title":"Eur Urol"},{"key":"4571_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.eururo.2016.11.031","volume":"71","author":"J He","year":"2017","unstructured":"He J, Albertsen PC, Moore D, Rotter D, Demissie K, Lu-Yao G Validation of a contemporary five-tiered gleason grade grouping using population-based data. Eur Urol. 2017;71:760\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.031.","journal-title":"Eur Urol"},{"key":"4571_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, et al. MRI-Targeted, Systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1910038.","journal-title":"N Engl J Med"},{"key":"4571_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.050.","journal-title":"Eur Urol"},{"key":"4571_CR9","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T","volume":"70","author":"A Villers","year":"1992","unstructured":"Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the Prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer. 1992;70:2313\u20138.","journal-title":"Cancer"},{"key":"4571_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0090-4295(02)01728-4","volume":"60","author":"AM Wise","year":"2002","unstructured":"Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264\u20139. https:\/\/doi.org\/10.1016\/S0090-4295(02)01728-4.","journal-title":"Urology"},{"key":"4571_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.plipres.2013.01.001","volume":"52","author":"MD Lloyd","year":"2013","unstructured":"Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ. \u03b1-Methylacyl-CoA racemase (AMACR): metabolic Enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013;52:220\u201330. https:\/\/doi.org\/10.1016\/j.plipres.2013.01.001","journal-title":"Prog Lipid Res"},{"key":"4571_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.humpath.2011.11.005","volume":"43","author":"F Brimo","year":"2012","unstructured":"Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012;43:313\u201324. https:\/\/doi.org\/10.1016\/j.humpath.2011.11.005.","journal-title":"Hum Pathol"},{"key":"4571_CR13","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.ajpath.2014.04.012","volume":"184","author":"AA Madigan","year":"2014","unstructured":"Madigan AA, Rycyna KJ, Parwani AV, Datiri YJ, Basudan AM, Sobek KM, Cummings JL, Basse PH, Bacich DJ, O\u2019Keefe DS. Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness. Am J Pathol. 2014;184:2156\u201362. https:\/\/doi.org\/10.1016\/j.ajpath.2014.04.012.","journal-title":"Am J Pathol"},{"key":"4571_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/jnci\/djp030","volume":"101","author":"T Migita","year":"2009","unstructured":"Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. JNCI: J Natl Cancer Inst. 2009;101:519\u201332. https:\/\/doi.org\/10.1093\/jnci\/djp030.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"4571_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0046-8177(96)90218-X","volume":"27","author":"MS Shurbaji","year":"1996","unstructured":"Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol. 1996;27:917\u201321. https:\/\/doi.org\/10.1016\/S0046-8177(96)90218-X.","journal-title":"Hum Pathol"},{"key":"4571_CR16","first-page":"5975","volume":"59","author":"MJ Bussemakers","year":"1999","unstructured":"Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: A new prostate-Specific Gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975\u20139.","journal-title":"Cancer Res"},{"key":"4571_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","volume":"69","author":"LS Marks","year":"2007","unstructured":"Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SMJ, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, et al. PCA3 Molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532\u20135. https:\/\/doi.org\/10.1016\/j.urology.2006.12.014","journal-title":"Urology"},{"key":"4571_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.eururo.2008.07.027","volume":"54","author":"S Loeb","year":"2008","unstructured":"Loeb S. Does PCA 3 help identify clinically significant prostate Cancer?. Eur Urol. 2008;54:980\u20131. https:\/\/doi.org\/10.1016\/j.eururo.2008.07.027.","journal-title":"Eur Urol"},{"key":"4571_CR19","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","volume":"179","author":"H Nakanishi","year":"2008","unstructured":"Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804\u201310. https:\/\/doi.org\/10.1016\/j.juro.2008.01.013.","journal-title":"J Urol"},{"key":"4571_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/pros.20781","volume":"68","author":"MPMQ van Gils","year":"2008","unstructured":"van Gils MPMQ, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CFJ, Mulders PFA, Rittenhouse HG, Schalken JA. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008;68:1215\u201322. https:\/\/doi.org\/10.1002\/pros.20781.","journal-title":"Prostate"},{"key":"4571_CR21","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s13277-013-0739-6","volume":"34","author":"X Filella","year":"2013","unstructured":"Filella X, Foj L, Mil\u00e0 M, Aug\u00e9 JM, Molina R, Jim\u00e9nez W. PCA3 in the detection and management of early prostate cancer. Tumor Biol. 2013;34:1337\u201347. https:\/\/doi.org\/10.1007\/s13277-013-0739-6.","journal-title":"Tumor Biol"},{"key":"4571_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/pros.21032","volume":"70","author":"D Hessels","year":"2010","unstructured":"Hessels D, van Gils MPMQ, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, Schalken JA. Predictive value of PCA3 in urinary sediments in determining Clinico-Pathological characteristics of prostate cancer. Prostate. 2010;70:10\u20136. https:\/\/doi.org\/10.1002\/pros.21032.","journal-title":"Prostate"},{"key":"4571_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","volume":"183","author":"JJ Tosoian","year":"2010","unstructured":"Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ. Accuracy of PCA3 measurement in predicting Short-Term biopsy progression in an active surveillance program. J Urol. 2010;183:534\u20138. https:\/\/doi.org\/10.1016\/j.juro.2009.10.003.","journal-title":"J Urol"},{"issue":"10","key":"4571_CR24","first-page":"4657","volume":"33","author":"SD Luca","year":"2013","unstructured":"Luca SD, Passera R, Bollito E, Milillo A, Scarpa RM, Papotti M, Coda R, Randone DF. Biopsy and radical prostatectomy pathological patterns influence prostate cancer gene 3 (PCA3) score. Anticancer Res. 2013;33(10):4657\u201362.","journal-title":"Anticancer Res"},{"key":"4571_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1464-410X.2011.10377.x","volume":"109","author":"H van Poppel","year":"2012","unstructured":"van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109:360\u20136. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10377.x.","journal-title":"BJU Int"},{"key":"4571_CR26","doi-asserted-by":"publisher","first-page":"37496","DOI":"10.1074\/jbc.M006293200","volume":"275","author":"GW Verhaegh","year":"2000","unstructured":"Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJG. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem. 2000;275:37496\u2013503. https:\/\/doi.org\/10.1074\/jbc.M006293200.","journal-title":"J Biol Chem"},{"key":"4571_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","volume":"133","author":"H Kawabata","year":"2019","unstructured":"Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med. 2019;133:46\u201354. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.06.037.","journal-title":"Free Radic Biol Med"},{"key":"4571_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/pros.10290","volume":"57","author":"A van Bokhoven","year":"2003","unstructured":"van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57:205\u201325. https:\/\/doi.org\/10.1002\/pros.10290.","journal-title":"Prostate"},{"key":"4571_CR29","doi-asserted-by":"publisher","first-page":"110000","DOI":"10.1016\/j.compbiomed.2025.110000","volume":"189","author":"L Li","year":"2025","unstructured":"Li L, Cho KH, Yu X, Cheng S. Systematic multi-omics investigation of androgen receptor driven gene expression and epigenetics changes in prostate cancer. Comput Biol Med. 2025;189:110000. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110000.","journal-title":"Comput Biol Med"},{"key":"4571_CR30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.clinbiochem.2008.06.013","volume":"41","author":"AF Neves","year":"2008","unstructured":"Neves AF, Ara\u00fajo TG, Biase WKFS, Meola J, Alc\u00e2ntara TM, Freitas DG, Goulart LR. Combined analysis of multiple MRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem. 2008;41:1191\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.06.013.","journal-title":"Clin Biochem"},{"key":"4571_CR31","doi-asserted-by":"publisher","unstructured":"Yue QH, Hu XB, Yin Y, Su MQ, Cheng XD, Yang L, Zhou TC, Hao X. Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes. Oncol Rep. 2009. https:\/\/doi.org\/10.3892\/or_00000573.","DOI":"10.3892\/or_00000573"},{"key":"4571_CR32","doi-asserted-by":"publisher","first-page":"e35153","DOI":"10.1371\/journal.pone.0035153","volume":"7","author":"M Ding","year":"2012","unstructured":"Ding M, Cao X, Xu H, Fan J, Huang H, Yang D, Li Y, Wang J, Li R, Liu X-Y. Prostate Cancer-Specific and potent antitumor effect of a DD3-Controlled oncolytic virus harboring the PTEN gene. PLoS ONE. 2012;7:e35153. https:\/\/doi.org\/10.1371\/journal.pone.0035153.","journal-title":"PLoS ONE"},{"key":"4571_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Galante JR, Haroon A, Wan S, Afaq A, Payne H, Bomanji J, Adeleke S, Kasivisvanathan V. The future of PSMA PET and WB MRI as Next-Generation imaging tools in prostate cancer. Nat Rev Urol. 2022;19:475\u201393. https:\/\/doi.org\/10.1038\/s41585-022-00618-w.","journal-title":"Nat Rev Urol"},{"key":"4571_CR34","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/cancers12061367","volume":"12","author":"W Jones","year":"2020","unstructured":"Jones W, Griffiths K, Barata PC, Paller CJPSMA, Theranostics. Review of the current status of PSMA-Targeted imaging and radioligand therapy. Cancers. 2020;12:1367. https:\/\/doi.org\/10.3390\/cancers12061367.","journal-title":"Cancers"},{"key":"4571_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, Haas GP. Expression of Prostate-Specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628\u201336. https:\/\/doi.org\/10.1007\/s00268-005-0544-5.","journal-title":"World J Surg"},{"key":"4571_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, et al. Prostate-Specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04571-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:53:50Z","timestamp":1774432430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04571-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4571"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04571-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not application.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"473"}}